Dialybrid secures €15 million series A round and announces successful first-in-human implant of novel Silkothane® Arteriovenous Graft for vascular access in hemodialysisCantù, Italy, September 22nd, 2026, Dialybrid S.r.l. (Dialybrid), a privately held medical device company developing a novel vascular access solution for hemodialysis based on Silkothane®, a patented hybrid material made up of silk fibroin and polyurethane, announced today the closing of a €15 million series A round led by new investor XGEN Venture, with participation of CDP Venture Capital (Rilancio Fund).
